Cargando…

Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis.

While conventional approaches for inflammatory bowel diseases (IBD) mainly focus on suppressing hyperactive immune responses, it remains unclear how to address disrupted intestinal barriers, dysbiosis of the gut commensal microbiota, and dysregulated mucosal immune responses in IBD. Moreover, immuno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yonghyun, Sugihara, Kohei, Gillilland, Merritt G., Jon, Sangyong, Kamada, Nobuhiko, Moon, James J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923573/ https://www.ncbi.nlm.nih.gov/pubmed/31427744 http://dx.doi.org/10.1038/s41563-019-0462-9

Ejemplares similares

Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy
por: Lee, Yonghyun, et al.
Publicado: (2023)

A bilirubin-derived nanomedicine attenuates the pathological cascade of pulmonary fibrosis
por: Keum, Hyeongseop, et al.
Publicado: (2021)

Biotinylated Bilirubin Nanoparticles as a Tumor Microenvironment‐Responsive Drug Delivery System for Targeted Cancer Therapy
por: Lee, Yonghyun, et al.
Publicado: (2018)

Diet–Microbiota Interactions in Inflammatory Bowel Disease
por: Sugihara, Kohei, et al.
Publicado: (2021)

Hyaluronic Acid-Based Theranostic Nanomedicines for Targeted Cancer Therapy
por: Lee, So Yun, et al.
Publicado: (2020)

Unconjugated bilirubin alleviates experimental ulcerative colitis by regulating intestinal barrier function and immune inflammation
por: Zheng, Jia-Dong, et al.
Publicado: (2019)

PEGylated Bilirubin-coated Iron Oxide Nanoparticles as a Biosensor for Magnetic Relaxation Switching-based ROS Detection in Whole Blood
por: Lee, Dong Yun, et al.
Publicado: (2020)

Can bilirubin nanomedicine become a hope for the management of COVID-19?
por: Khurana, Isha, et al.
Publicado: (2021)

Hyaluronic Acid-Coated Nanomedicine for Targeted Cancer Therapy
por: Kim, Kibeom, et al.
Publicado: (2019)

Hyaluronic Acid Nanoparticles as Nanomedicine for Treatment of Inflammatory Diseases
por: Rao, N.Vijayakameswara, et al.
Publicado: (2020)

The Role of Dietary Nutrients in Inflammatory Bowel Disease
por: Sugihara, Kohei, et al.
Publicado: (2019)

Modulation of Gut Barrier Functions in Ulcerative Colitis by Hyaluronic Acid System
por: Kotla, Niranjan G., et al.
Publicado: (2021)

Nanomedicine Faces Barriers
por: Debbage, Paul, et al.
Publicado: (2010)

Unconjugated Bilirubin Attenuates DSS-Induced Colitis Potentially via Enhancement of Bilirubin Reabsorption
por: Zhao, Chong, et al.
Publicado: (2021)

Smart pH-responsive nanomedicines for disease therapy
por: Shinn, Jongyoon, et al.
Publicado: (2022)

Focus on nanomedicine molecular science
por: Ishihara, Kazuhiko, et al.
Publicado: (2016)

Bilirubin Nanoparticles Protect Against Cardiac Ischemia/Reperfusion Injury in Mice
por: Ai, Wen, et al.
Publicado: (2021)

Reduced total serum bilirubin levels are associated with ulcerative colitis
por: Schieffer, Kathleen M., et al.
Publicado: (2017)

Slimy partners: the mucus barrier and gut microbiome in ulcerative colitis
por: Fang, Jian, et al.
Publicado: (2021)

Self-Assembling β-Glucan Nanomedicine for the Delivery of siRNA
por: Lee, Kyungwoo, et al.
Publicado: (2020)

Amelioration of ulcerative colitis via inflammatory regulation by macrophage-biomimetic nanomedicine
por: Sun, Tianlei, et al.
Publicado: (2020)

Unconjugated bilirubin ameliorates the inflammation and digestive protease increase in TNBS-induced colitis
por: Zhou, Jin-An, et al.
Publicado: (2017)

Clinical Utility of the Neutrophil-to-Bilirubin Ratio in the Detection of Disease Activity in Ulcerative Colitis
por: Huang, Xijing, et al.
Publicado: (2023)

Clinical significance of the C-reactive protein-to-bilirubin ratio in patients with ulcerative colitis
por: Huang, Xijing, et al.
Publicado: (2023)

NIR Laser-Responsive PNIPAM and Gold Nanorod Composites for the Engineering of Thermally Reactive Drug Delivery Nanomedicine
por: Kwon, Yejin, et al.
Publicado: (2020)

Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment
por: Tanaka, Hiroyoshi Y., et al.
Publicado: (2018)

Overcoming Vascular Barriers to Improve the Theranostic Outcomes of Nanomedicines
por: Tang, Yufu, et al.
Publicado: (2022)

Role of Bilirubin in Diabetic Vascular Complications: Can Bilirubin Predict More than Just Liver Disease?
por: Moon, Jun Sung
Publicado: (2015)

Dysregulation of the Intestinal Microbiome in Patients With Haploinsufficiency of A20
por: Toyofuku, Etsushi, et al.
Publicado: (2022)

Decreased Serum Bilirubin Levels and Increased Uric Acid Levels are Associated with Ulcerative Colitis
por: Tian, Shan, et al.
Publicado: (2018)

FATE OF BILIRUBIN IN THE SMALL INTESTINE
por: Sackey, M. S., et al.
Publicado: (1934)

Dietary phosphate exacerbates intestinal inflammation in experimental colitis
por: Sugihara, Kohei, et al.
Publicado: (2017)

Secondary bile acids mediate high-fat diet–induced upregulation of R-spondin 3 and intestinal epithelial proliferation
por: Li, Ji-Yao, et al.
Publicado: (2022)

Inner ear barriers to nanomedicine-augmented drug delivery and imaging()
por: Zou, Jing, et al.
Publicado: (2016)

Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme
por: Jena, Lynn, et al.
Publicado: (2019)

Post Transplantation Bilirubin Nanoparticles Ameliorate Murine Graft Versus Host Disease via a Reduction of Systemic and Local Inflammation
por: Pareek, Sumedha, et al.
Publicado: (2022)

Mulberry Biomass-Derived Nanomedicines Mitigate Colitis through Improved Inflamed Mucosa Accumulation and Intestinal Microenvironment Modulation
por: Yang, Wenjing, et al.
Publicado: (2023)

Qingchang Wenzhong Decoction Accelerates Intestinal Mucosal Healing Through Modulation of Dysregulated Gut Microbiome, Intestinal Barrier and Immune Responses in Mice
por: Sun, Zhongmei, et al.
Publicado: (2021)

Oral polyphenol-armored nanomedicine for targeted modulation of gut microbiota–brain interactions in colitis
por: He, Huan, et al.
Publicado: (2023)

Advances in natural compound-based nanomedicine and the interaction with gut microbiota in ulcerative colitis therapy
por: Zhang, Jinlan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_02ad6hh29b30kfoajvmr2tmprn